---
title: "Abbott Laboratories (ABT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABT.US.md"
symbol: "ABT.US"
name: "Abbott Laboratories"
industry: "Health Care Equipment"
datetime: "2026-04-17T00:39:47.898Z"
locales:
  - [en](https://longbridge.com/en/quote/ABT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABT.US.md)
---

# Abbott Laboratories (ABT.US)

## Company Overview

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.abbott.com](https://www.abbott.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:16.000Z

**Overall: B (0.38)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.67% |  |
| Net Profit YoY | -51.49% |  |
| P/B Ratio | 3.39 |  |
| Dividend Ratio | 2.40% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 176599834937.32 |  |
| Revenue | 44328000000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.03% | B |
| Profit Margin | 14.72% | B |
| Gross Margin | 56.66% | B |
| Revenue YoY | 5.67% | C |
| Net Profit YoY | -51.49% | D |
| Total Assets YoY | 6.51% | B |
| Net Assets YoY | 10.17% | B |
| Cash Flow Margin | 147.17% | B |
| OCF YoY | 5.67% | C |
| Turnover | 0.53 | C |
| Gearing Ratio | 39.14% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Abbott Laboratories",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.67%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-51.49%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.39",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.40%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "176599834937.32",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "44328000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.03%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "14.72%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "56.66%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "5.67%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-51.49%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.51%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.17%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "147.17%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "5.67%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "39.14%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 27.17 | 23/183 | 27.39 | 16.72 | 15.81 |
| PB | 3.39 | 82/183 | 4.71 | 4.43 | 3.83 |
| PS (TTM) | 3.98 | 81/183 | 5.42 | 5.10 | 4.46 |
| Dividend Yield | 2.40% | 6/183 | 2.12% | 1.84% | 1.73% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Abbott Laboratories (ABT.US) | B | C | C | C | B | B |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | B | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | B | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-16T04:00:00.000Z

Total Analysts: **29**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 16 | 55% |
| Overweight | 6 | 21% |
| Hold | 7 | 24% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 95.47 |
| Highest Target | 158.00 |
| Lowest Target | 113.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ABT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ABT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ABT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ABT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**